Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025

Annexon, Inc.

ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.
ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.
ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.
Cash runway sufficient into 2H 2026 to achieve key milestones.
Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.